Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Eating Beans, Vegetables May Reduce MS Risk

Eating a lot of green leafy and other vegetables, beans, nuts and berries seems to significantly lower the likelihood of developing multiple sclerosis (MS), according to a study from Iran. The findings also suggest that the chances of developing the disease may be higher in people who eat more…

Vumerity Added to NHS of Scotland for People With Active RMMS

Note: An earlier version of this story stated the Scottish Medicines Consortium approved Vumerity for RRMS patients in that country. The consortium decides to add a medicine to Scotlandā€™s National Health Service; the MHRA approves treatments for England, Scotland, and Wales. The Scottish Medicines Consortium has approved adding the…

Atara, Fujifilm Enter Deal to Produce Cell Therapies

Atara Biotherapeutics has reached an agreement withĀ Fujifilm Diosynth Biotechnologies for the production of its cell therapy pipeline, including ATA188, an experimental therapy being investigated for the treatment of progressive multiple sclerosis (MS). Under the agreement, Fujifilm will acquire Ataraā€™s T-Cell Operations and Manufacturing (ATOM) facility in Thousand…

How Vitamin D Modulates Immune System Activity Detailed in Study

Vitamin D can influence the immune system’s tolerance to certain proteins by changing how DNA is packaged in specific immune cells called dendritic cells, according to a new study. Its findings could have implications for treating diseases like multiple sclerosis (MS) that are characterized by the immune system attacking…

Imaging Brain Metabolites May Help Diagnose, Monitor MS

A new imaging technique called magnetic resonance spectroscopic imaging, or MRSI, could be useful for diagnosing and monitoring multiple sclerosis (MS), according to a small study. “If confirmed in longitudinal clinical studies, this new neuroimaging technique could become a standard imaging tool for initial diagnosis, for disease progression and…

Study Probes Why Some Don’t Experience Placebo Effect

Differences in the physical architecture of the brain may explain why some people with multiple sclerosis (MS), but not others, experience a placebo effect, according to a new study. The results suggest that MS itself may make some individuals unable to experience the benefits of a placebo. “Our findings…

Acthar Gel May Help RRMS Patients Who Fail Corticosteroids

Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…

New Machine Learning Algorithm Could Help in Diagnosing MS Sooner

A new machine learning algorithm ā€” designed to analyze healthcare records ā€” could help in diagnosing multiple sclerosis (MS) sooner by identifying patients’ symptoms earlier. The algorithm, devised by scientists at the University of California San Francisco (UCSF), was described in a study titled “Embedding electronic health records…

Top 10 Multiple Sclerosis Stories of 2021

Multiple Sclerosis News TodayĀ brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…

Results From Trial of Simvastatin for SPMS Expected in 2025

MS-STAT2, a clinical trial testing whether the cholesterol-lowering medication simvastatin might slow disability progression in secondary progressive multiple sclerosis (SPMS), has finished enrollment. A total of 964 people are now in the trial (NCT03387670), making it the largest progressive MS trial not run by a commercial…

Little Evidence Acthar Gel Better Than Cheaper Substitutes: Review

There is minimal evidence that the expensive anti-inflammatory medication Acthar Gel (repository corticotropin injection) is more effective than inexpensive corticosteroids for the treatment of multiple sclerosis (MS) and other diseases, according to a new review paper. “We found no evidence where it was a conclusive slam dunk that…